Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021
Amicus Therapeutics (Nasdaq: FOLD) will host a conference call on March 1, 2021, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020. Investors can join the call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international) with conference ID 6959755. A live audio webcast will also be available on the company's website. A replay will be accessible for seven days following the call. Amicus is focused on developing high-quality medicines for rare metabolic diseases.
- Upcoming conference call to discuss financial results indicates transparency and engagement with investors.
- None.
PHILADELPHIA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 1, 2021 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2020.
Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 6959755. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.
A replay of the call will be available for seven days beginning at 11:30 a.m. ET. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 6959755.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACT:
Investors:
Andrew Faughnan
Sr. Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
When will Amicus Therapeutics announce its financial results for 2020?
How can I participate in the Amicus Therapeutics conference call?
Where can I access the Amicus Therapeutics financial results webcast?